Myriad Genetics, Inc.

Myriad Genetics, Inc. Earnings Recaps

MYGN Health Care 2 recaps
Next earnings: March 2, 2027 (estimated) · full calendar
Q3 2026 Nov 7, 2026

Myriad’s shares rose 4.5% after earnings, with investors likely responding to a modestly higher 2026 revenue outlook, sequential improvement in average revenue per test and the $210 million agreement to sell its Prenatal Health business. The quarter still showed pressure in Prenatal Health volumes and year-over-year declines in Cancer Care average revenue per test.

Key takeaways
  • Q3 revenue was $202.7 million. Cancer Care Continuum and Mental Health test volumes grew 4% and 3% year over year, respectively; Prenatal Health volume fell 11%.
  • Average revenue per test increased 1% year over year, versus a 9% decline in Q2. HCT revenue per test was down 6% year over year but up 9% sequentially.
  • Cancer Care Continuum revenue was $124 million, up 1% year over year. Test volume rose 4% to 98,000, while average revenue per test declined 3%.
  • Gross margin improved 130 basis points from Q2 to 67.9%. Adjusted EBITDA improved by $5.3 million quarter over quarter to negative $5.3 million; adjusted EPS was negative $0.11.
  • Myriad raised the midpoint of 2026 revenue guidance modestly, to a range of $780 million to $790 million. The Prenatal Health sale to Labcorp is an all-cash deal for $210 million plus inventory.
Q1 2026 May 7, 2026

Shares dropped 16.8% following the quarter, reflecting investor disappointment with margin compression and cautious outlook despite steady revenue growth and reaffirmed guidance.

Key takeaways
  • Q1 revenue of just over $200 million came within guided range, driven by 10% and 16% growth in hereditary cancer testing volumes in affected and unaffected populations, respectively.
  • GeneSight mental health test volume grew 7% year-over-year, marking the fourth consecutive quarter of mid-to-high single-digit growth.
  • Prenatal testing volumes declined year-over-year but management targets a recovery in the second half of 2026.
  • Gross margin held at 69%, consistent with full-year expectations, but adjusted EBITDA loss of $4.5 million and EPS loss of $0.09 signal margin pressure amid significant commercial and R&D investments.
  • The company reaffirmed 2026 guidance, expecting low single-digit sequential revenue growth and positive adjusted EBITDA, but cautious outlook and ongoing investments weighed on investor sentiment.